2020
Replicated risk CACNA1C variants for major psychiatric disorders may serve as potential therapeutic targets for the shared depressive endophenotype.
Guo X, Fu Y, Zhang Y, Wang T, Lu L, Luo X, Wang K, Huang J, Xie T, Zheng C, Yang K, Tong J, Zuo L, Kang L, Tan Y, Jiang K, Li CR, Luo X. Replicated risk CACNA1C variants for major psychiatric disorders may serve as potential therapeutic targets for the shared depressive endophenotype. 2020, 4 PMID: 34046650, PMCID: PMC8153461.Peer-Reviewed Original ResearchMajor psychiatric disordersGenome-wide association studiesL-type voltage-gated calcium channelsMajor depressive disorderMRNA expression regulationPsychiatric disordersTherapeutic targetBipolar disorderChronic mild stress (CMS) ratsHuman hippocampusExpression regulationDepressive endophenotypeType voltage-gated calcium channelsRole of venlafaxineVoltage-gated calcium channelsPotential therapeutic targetRisk genesSignificant mRNA expressionVenlafaxine treatmentDepressive disorderStress ratsDepressive symptomsIndependent cohortCalcium channelsMRNA expression
2016
The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder
Cao Y, Shen J, Li W, Zhang Y, Guo X, Li C, Zhang Y, Luo X. The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder. Asia-Pacific Psychiatry 2016, 8: 309-311. PMID: 27015764, PMCID: PMC5035708, DOI: 10.1111/appy.12240.Peer-Reviewed Original ResearchConceptsClinical remissionChinese patientsSymptom trajectoriesUnipolar major depressive disorderMajor depressive disorder symptomsWeeks of assessmentMajor depressive disorderTreatment of fluoxetineDepressive disorder symptomsDepressive disorderTreatment responseProminent symptomWeek 1Psychomotor retardationRemissionSymptom severityPatientsDisorder symptomsFluoxetineSymptomsSeverityWeeksTreatmentOutpatientsShow heterogeneity